



Name	Haeryoung Kim
Affiliation	Seoul National University Hospital
Country	Republic of Korea
Major Field	Liver and pancreaticobiliary pathology

Educational Background	
2005 – 2008	Ph.D., Pathology, Yonsei University Graduate College of Medicine
2001 – 2003	M.S., Molecular Genetics and Pathology, BK (Brain Korea) 21 Project for Medical Sciences, Yonsei University Graduate College of Medical Sciences
1994 – 2000	Medicine, Yonsei University College of Medicine

Professional Experience
2019–present: Professor, Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine
2017–2019 Associate Professor, Department of Pathology, Seoul National University Hospital
2012–2017 Associate Professor, Department of Pathology, Seoul National University Bundang Hospital
2012–2013 Visiting postdoctoral fellow, GI & Liver Pathology, Johns Hopkins Hospital, Baltimore, MD, USA (Early Pancreatic Cancer Detection Laboratory)
2008–2012 Assistant Professor, Department of Pathology, Seoul National University Bundang Hospital
2006–2008 Instructor, Department of Pathology, Seoul National University Bundang Hospital
2006 Clinical Fellow, Department of Pathology, Seoul National University Bundang Hospital
2005–2006 Clinical Fellow, Department of Pathology, Severance Hospital, Yonsei University
2001–2005 Residency, Department of Pathology, Severance Hospital, Yonsei University



Main Scientific Publications

Hwang YJ, Lee H, Hong SK, Yu SJ, Kim H. Membranous Overexpression of Fibronectin Predicts Microvascular Invasion and Poor Survival Outcomes in Patients with Hepatocellular Carcinoma. *Gut Liver*. 2025 Mar 15;19(2):275-285.

Hwang YJ, Lee Y, Yu SJ, Hong SK, Yi NJ, Choi Y, Lee H, Chung W, Kim H. Correlation between CTNNB1 mutation status and tumour phenotype in hepatitis B virus-related hepatocellular carcinoma. *Histopathology*. 2025 Mar;86(4):547-558.

Jang B, Kwon SM, Kim JH, Kim JM, Chung T, Yoo JE, Kim H, Calderaro J, Woo HG, Park YN. Transcriptomic profiling of intermediate cell carcinoma of the liver. *Hepatol Commun*. 2024 Aug 5;8(8):e0505.

Ahn S, Jeong SH, Cho EJ, Lee K, Kim G, Kim H. Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity. *Clin Mol Hepatol*. 2024;30(1):37-48.

Hwang YJ, Bae JS, Lee Y, Hur BY, Lee DH, Kim H. Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging. *Clin Mol Hepatol*. 2023;29(3):733-746.

Oh MY, Kim H, Yi NJ, Hong S, Lee JM, Lee S, Hong SK, Choi Y, Lee KW, Suh KS. The fate of donor-type ABO blood group antigen expression in liver grafts in ABO-incompatible adult living donor liver transplantation. *J Hepatobiliary Pancreat Sci*. 2023;30(7):871-881.

Kwon M, Hong SM, Lee K, Kim H. Liquid-based cytology features of pancreatic acinar cell carcinoma: comparison with other non-ductal neoplasms of the pancreas. *J Pathol Transl Med*. 2024 Jul;58(4):182-190.

Kim, Leow, Mendoza, Lo, Chan. *Atlas of Hepatocellular Carcinoma Pathology*. Springer. 2022
Leow WQ, Chan AW, Mendoza PGL, Lo R, Yap K, Kim H. Non-alcoholic fatty liver disease: the pathologist's perspective. *Clin Mol Hepatol*. 2022 Nov 15. doi: 10.3350/cmh.2022.0329.

Calderaro J, Ghaffari Laleh N, Zeng Q, et al. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma. *Nat Commun*. 2023;14(1):8290.

Calderaro J, Di Tommaso L, Maillé P, et al. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. *J Hepatol*. 2022 Dec;77(6):1586-1597. doi: 10.1016/j.jhep.2022.07.019. Epub 2022 Aug 18.

Park SE, Lee Y, Kim H, Yu MH, Lee ES, Yoon JH, Joo I, Lee JM. Subtype classification of intrahepatic cholangiocarcinoma using liver MRI imaging features and its prognostic value. *Liver Cancer* 2022 Mar 30;11(3):233-246.